Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115851 | 1.00 | L3MBTL1 (0.56) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL18288692 | 0.93 | L3MBTL1 (0.63) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL29395178 | 0.91 | L3MBTL1 (0.45) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL18288634 | 0.87 | L3MBTL1 (0.56) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2609692 | 0.86 | L3MBTL1 (0.54) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL2113769 | 0.81 | HCAR2 (0.46) | L3MBTL1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL2113770 | 0.81 | HCAR2 (0.46) | L3MBTL1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL18288674 | 0.80 | L3MBTL1 (0.47) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL19710848 | 0.77 | L3MBTL1 (0.44) | L3MBTL1RAB9APOLBNPC1ALDH1A1 | |
| SCHEMBL18288645 | 0.77 | L3MBTL1 (0.57) | L3MBTL1RAB9ANPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | claimed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | claimed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | RAJASEKHAR VIJAYKUMAR (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170216242-A1 | METHODS OF TREATING HEART FAILURE DISEASES USING PRODRUGS OF METHYL HYDROGEN FUMARATE | RAJASEKHAR VIJAYKUMAR (US) | 2017-08-03 | — | — | US | disclosed |
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016061393-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | disclosed |
| US-8952006-B2 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | XENOPORT, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | XENOPORT, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | L3MBTL1 2968/4885RAB9A 3011/4885POLB 1143/4885 |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | FH, APC, HTT | L3MBTL1 1726/4885RAB9A 3322/4885POLB 183/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | L3MBTL1 3271/4885RAB9A 3060/4885POLB 1066/4885 |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | L3MBTL1 3271/4885RAB9A 3060/4885POLB 1066/4885 |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | FH, APC, HTT | L3MBTL1 1726/4885RAB9A 3322/4885POLB 183/4885 |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | FH, HMGCR, HPGD | L3MBTL1 1875/4885RAB9A 3217/4885POLB 2508/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | L3MBTL1 2968/4885RAB9A 3011/4885POLB 1143/4885 |
| US-20170216242-A1 | METHODS OF TREATING HEART FAILURE DISEASES USING PRODRUGS OF METHYL HYDROGEN FUMARATE | FH, HMGCR, HPGD | L3MBTL1 1875/4885RAB9A 3217/4885POLB 2508/4885 |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | L3MBTL1 3271/4885RAB9A 3060/4885POLB 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.